Vimarsana
Biggest News Aggregation in the World

Page 9 - Bin Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bin Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bin Chen Today - Breaking & Trending Today

Mysterious 'heartbeat' is coming from our SUN: Scientists detect repeating pattern in a solar flare - Vimarsana News

Mysterious 'heartbeat' is coming from our SUN: Scientists detect repeating pattern in a solar flare

The heartbeat-like signal, which baffles scientists, repeats every 10 to 20 seconds. US scientists located the pattern to a C-class solar flare bursting more than 3,100 miles above the sun's surface.

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) - Vimarsana News

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) - Vimarsana News

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT No New... | February 18, 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut - Vimarsana News

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La...

NU researchers develop highly efficient solar cell - Vimarsana News

NU researchers develop highly efficient solar cell

Each rainbow features the full range of the electromagnetic spectrum, including wavelengths from red to violet and beyond. But, these wavelengths can present an obstacle for scientists working to harness energy from the sun. In response to this challenge, Northwestern researchers have co-developed a “perovskite tandem” solar cell that can better absorb sunlight of all...